B

Briggs, E. M., Marques, C. A. , Oldrieve, G. R., Hu, J., Otto, T. D. and Matthews, K. R. (2023) Profiling the bloodstream form and procyclic form Trypanosoma brucei cell cycle using single cell transcriptomics. eLife, (doi: 10.7554/eLife.86325) (Early Online Publication)

Britton, C. , Laing, R. , McNeilly, T. N., Perez, M. G. , Otto, T. D. , Hildersley, K. A., Maizels, R. M. , Devaney, E. and Gillan, V. (2023) New technologies to study helminth development and host-parasite interactions. International Journal for Parasitology, (doi: 10.1016/j.ijpara.2022.11.012) (PMID:36931423) (In Press)

C

Challoumas, D., Zouvani, A., Creavin, K., Murray, E., Crosbie, G., Ng, N. and Millar, N. L. (2023) Determining minimal important differences for patient-reported outcome measures in shoulder, lateral elbow, patellar and Achilles tendinopathies using distribution-based methods. BMC Musculoskeletal Disorders, 24, 158. (doi: 10.1186/s12891-023-06261-9) (PMID:36864412) (PMCID:PMC9979571)

Chawla, J. et al. (2023) Phenotypic screens identify genetic factors associated with gametocyte development in the human malaria parasite Plasmodium falciparum. Microbiology Spectrum, (doi: 10.1128/spectrum.04164-22) (PMID:37154686) (Early Online Publication)

Chong, H. Y. et al. (2023) Cost-effectiveness of cognitive behavioural and personalised exercise interventions for reducing fatigue in inflammatory rheumatic diseases. Rheumatology, (doi: 10.1093/rheumatology/kead157) (PMID:37018151) (Early Online Publication)

Coates, L. C. et al. (2023) Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC. Rheumatology, 62(1), e1-e3. (doi: 10.1093/rheumatology/keac388) (PMID:35799375)

Conrad, N., McInnes, I. B. , Mcmurray, J. J.V. and Sattar, N. (2023) Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR)'s recommendations for cardiovascular risk management? Annals of the Rheumatic Diseases, 82(4), pp. 457-459. (doi: 10.1136/ard-2022-223315) (PMID:36442979)

Conrad, N. et al. (2023) Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet, (doi: 10.1016/S0140-6736(23)00457-9) (In Press)

Cunningham, M. E. , McGonigal, R. , Barrie, J. A., Campbell, C. I., Yao, D. and Willison, H. J. (2023) Axolemmal nanoruptures arising from paranodal membrane injury induce secondary axon degeneration in murine Guillain-Barré syndrome. Journal of the Peripheral Nervous System, 28(1), pp. 17-31. (doi: 10.1111/jns.12532) (PMID:36710500)

E

Edwards, S. C. et al. (2023) PD-1 and TIM-3 differentially regulate subsets of mouse IL-17A–producing γδ T cells. Journal of Experimental Medicine, 220(2), e20211431. (doi: 10.1084/jem.20211431) (PMID:36480166) (PMCID:PMC9732671)

G

Gatt, Z., Gunes, U., Raponi, A., Camargo da Rosa, L. and Brewer, J. M. (2023) Review: Unravelling the role of DNA sensing in alum adjuvant activity. Discovery Immunology, 2(1), kyac012. (doi: 10.1093/discim/kyac012)

Gossec, L. et al. (2023) Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study. Annals of the Rheumatic Diseases, 82(4), pp. 496-506. (doi: 10.1136/ard-2022-222879) (PMID:36600178)

Gottlieb, A. B. et al. (2023) Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis. RMD Open, 9(1), e002789. (doi: 10.1136/rmdopen-2022-002789) (PMID:36828643) (PMCID:PMC9972414)

Gray, A. L. et al. (2023) Chemokine CXCL4 interactions with extracellular matrix proteoglycans mediate widespread immune cell recruitment independent of chemokine receptors. Cell Reports, 42(1), 111930. (doi: 10.1016/j.celrep.2022.111930) (PMID:36640356)

Gupta, L., Najm, A. , Kabir, K. and De Cock, D. (2023) Digital health in musculoskeletal care: where are we heading? BMC Musculoskeletal Disorders, 24, 192. (doi: 10.1186/s12891-023-06309-w) (PMID:36918856) (PMCID:PMC10012296)

H

Haese-Hill, W., Crouch, K. and Otto, T. D. (2023) peaks2utr: a robust Python tool for the annotation of 3’ UTRs. Bioinformatics, 39(3), btad112. (doi: 10.1093/bioinformatics/btad112) (PMID:36864613) (PMCID:PMC10008064)

Halstead, S. K. et al. (2023) Serum anti‐GM2 and anti‐GalNAc‐GD1a ganglioside IgG antibodies are biomarkers for immune‐mediated polyneuropathies in cats. Journal of the Peripheral Nervous System, 28(1), pp. 32-40. (doi: 10.1111/jns.12529) (PMID:36573790)

I

Iaconelli, A., Cuthbert, J., Kazmi, S., Maffia, P. , Clark, A. L., Cleland, J. G.F. and Pellicori, P. (2023) Inferior vena cava diameter is associated with prognosis in patients with chronic heart failure independent of tricuspid regurgitation velocity. Clinical Research in Cardiology, (doi: 10.1007/s00392-023-02178-4) (PMID:36894788) (Early Online Publication)

Iaconelli, A. et al. (2023) Coronary revascularization for heart failure with coronary artery disease: a systematic review and meta-analysis of randomized trials. European Journal of Heart Failure, (doi: 10.1002/ejhf.2911) (Early Online Publication)

J

Jatkowska, A. et al. (2023) Development and validation of the Glasgow Exclusive Enteral Nutrition Index of Compliance. Journal of Crohn's and Colitis, (doi: 10.1093/ecco-jcc/jjad063) (Accepted for Publication)

Johnsson, H., Cole, J., Siebert, S. , McInnes, I. B. and Graham, G. (2023) Cutaneous lesions in psoriatic arthritis are enriched in chemokine transcriptomic pathways. Arthritis Research and Therapy, 25, 73. (doi: 10.1186/s13075-023-03034-6)

K

Kennedy, J., Kennedy, N., Cooksey, R., Choy, E., Siebert, S. , Rahman, M. and Brophy, S. (2023) Predicting a diagnosis of ankylosing spondylitis using primary care health records–a machine learning approach. PLoS ONE, 18(3), e0279076. (doi: 10.1371/journal.pone.0279076)

L

Lindsay, S. L. , McCanney, G. A., Zhan, J., Scheld, M., Sherrard Smith, R., Goodyear, C. S. , Yates, E. A., Kipp, M., Turnbull, J. E. and Barnett, S. C. (2023) Low sulfated heparan sulfate mimetic differentially affects repair in immune-mediated and toxin-induced experimental models of demyelination. Glia, (doi: 10.1002/glia.24363) (PMID:36945189) (Early Online Publication)

Lindsay, S. L. , Sherrard-Smith, R., Yates, E. A., Cartwright, C., Thacker, B. E., Turnbull, J. E., Glass, C. A. and Barnett, S. C. (2023) Validation of recombinant heparan sulphate reagents for CNS repair. Biology, 12(3), 407. (doi: 10.3390/biology12030407) (PMID:36979099) (PMCID:PMC10044841)

M

Malcolm, J. et al. (2023) C-terminal citrullinated peptide alters antigen-specific APC:T cell interactions leading to breach of immune tolerance. Journal of Autoimmunity, 135, 102994. (doi: 10.1016/j.jaut.2023.102994) (PMID:36706535)

McGonigal, R. , Cunningham, M. E. , Smyth, D., Chou, M., Barrie, J. A., Wilkie, A., Campbell, C., Saatman, K. E., Lunn, M. and Willison, H. J. (2023) The endogenous calpain inhibitor calpastatin attenuates axon degeneration in murine Guillain-Barré syndrome. Journal of the Peripheral Nervous System, 28(1), pp. 4-16. (doi: 10.1111/jns.12520) (PMID:36335586)

McInnes, I. B. et al. (2023) Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet, 401(10370), pp. 25-37. (doi: 10.1016/S0140-6736(22)02302-9) (PMID:36493791)

McInnes, I. B. et al. (2023) Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 study. Rheumatology and Therapy, 10(1), pp. 275-292. (doi: 10.1007/s40744-022-00499-w) (PMID:36243812) (PMCID:PMC9569172)

Merola, J. F. et al. (2023) Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet, 401(10370), pp. 38-48. (doi: 10.1016/S0140-6736(22)02303-0) (PMID:36495881)

Morton, F. R. , Jani, B. D. , Mair, F. S. , McLoone, P. , Canning, J., Macdonald, S. , McQueenie, R., Siebert, S. and Nicholl, B. I. (2023) Association between risk, duration and cause of hospitalisations in people with rheumatoid arthritis and multimorbidity in the UK Biobank and Scottish Early Rheumatoid Arthritis (SERA) cohorts: longitudinal observational study. Seminars in Arthritis and Rheumatism, 58, 152130. (doi: 10.1016/j.semarthrit.2022.152130) (PMID:36459724)

Mumuni, A. N., Krishnadas, R. and Cavanagh, J. (2023) Peripheral inflammation is associated with alterations in brain biochemistry and mood: evidence from in vivo proton magnetic resonance spectroscopy study. Pure and Applied Chemistry, 95(3), pp. 289-300. (doi: 10.1515/pac-2022-1119)

N

Najm, A. (2023) Comment intégrer la santé numérique dans la prise en charge de patients atteints de rhumatismes inflammatoires? = Digital health in rheumatology: where do we stand? How much further do we need to go? Revue du Rhumatisme, (doi: 10.1016/j.rhum.2023.03.004) (In Press)

Najm, A. , Alunno, A. and Machado, P. (2023) COVID - how will it continue to change our lives? Joint Bone Spine, 90(4), 105572. (doi: 10.1016/j.jbspin.2023.105572) (PMID:37028643) (PMCID:PMC10126740)

Najm, A. , Goodyear, C. S. , McInnes, I. B. and Siebert, S. (2023) Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy. Nature Reviews Rheumatology, 19, pp. 153-165. (doi: 10.1038/s41584-022-00874-5) (PMID:36596924)

Nyirenda, M. H., Nijjar, J. S., Frleta-Gilchrist, M., Gilchrist, D. S., Porter, D., Siebert, S. , Goodyear, C. S. and McInnes, I. B. (2023) JAK inhibitors disrupt T cell-induced proinflammatory macrophage activation. RMD Open, 9(1), e002671. (doi: 10.1136/rmdopen-2022-002671) (PMID:36599629) (PMCID:PMC9815080)

P

Pærregaard, S. I. et al. (2023) The small and large intestine contain related mesenchymal subsets that derive from embryonic Gli1+ precursors. Nature Communications, 14, 2307. (doi: 10.1038/s41467-023-37952-5) (PMID:37085516) (PMCID:PMC10121680)

Pires, C. V. et al. (2023) Chemogenomic profiling of a Plasmodium falciparum transposon mutant library reveals shared effects of dihydroartemisinin and bortezomib on lipid metabolism and exported proteins. Microbiology Spectrum, (doi: 10.1128/spectrum.05014-22) (PMID:37067430) (Early Online Publication)

R

Rahman, P. et al. (2023) Safety of guselkumab with and without prior TNF-α inhibitor treatment: pooled results across four studies in patients with psoriatic arthritis. Journal of Rheumatology, (doi: 10.3899/jrheum.220928) (PMID:36642439) (Early Online Publication)

Robb, C. T. et al. (2023) Metabolic regulation by prostaglandin E2 impairs lung group 2 innate lymphoid cell responses. Allergy, 78(3), pp. 714-730. (doi: 10.1111/all.15541) (PMID:36181709)

S

Sattar, N. , McMurray, J. J. V. , McInnes, I. B. , Aroda, V. R. and Lean, M. E. J. (2023) Treating chronic diseases without tackling excess adiposity promotes multimorbidity. Lancet Diabetes and Endocrinology, 11(1), pp. 58-62. (doi: 10.1016/S2213-8587(22)00317-5) (PMID:36460014)

Siebert, S. , Behrens, F., Lubrano, E., Martin, N., Sharaf, M., Contré, C., Theander, E., Queiro, R., Zimmermann, M. and Gossec, L. (2023) PsABIOnd study and eDaily substudy design: long-term effectiveness and safety of guselkumab and IL-17 inhibitors in routine clinical practice in patients with psoriatic arthritis. Rheumatology and Therapy, 10(2), pp. 489-505. (doi: 10.1007/s40744-022-00518-w) (PMID:36585602)

Simmons, C. F. et al. (2023) Protein KIC5 is a novel regulator of artemisinin stress response in the malaria parasite Plasmodium falciparum. Scientific Reports, 13, 399. (doi: 10.1038/s41598-023-27417-6) (PMID:36624300) (PMCID:PMC9829687)

Smolen, J. S. et al. (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the Rheumatic Diseases, 82(1), pp. 3-18. (doi: 10.1136/ard-2022-223356) (PMID:36357155)

Smyth, D. J. , White, M. P.J., Johnston, C. J.C., Donachie, A.-M., Campillo Poveda, M. , McSorley, H. J. and Maizels, R. M. (2023) Protection from T cell-dependent colitis by the helminth-derived immunomodulatory mimic of transforming growth factor-ß, Hp-TGM. Discovery Immunology, 2(1), kyad001. (doi: 10.1093/discim/kyad001) (PMID:36855464) (PMCID:PMC9958376)

Sophocleous, A., Azfer, A., Huesa, C., Stylianou, E. and Ralston, S. H. (2023) Probiotics inhibit cartilage damage and progression of osteoarthritis in mice. Calcified Tissue International, 112(1), pp. 66-73. (doi: 10.1007/s00223-022-01030-7) (PMID:36261653) (PMCID:PMC9813193)

Steyer, A. M. et al. (2023) Focused ion beam-scanning electron microscopy links pathological myelin outfoldings to axonal changes in mice lacking Plp1 or Mag. Glia, 71(3), pp. 509-523. (doi: 10.1002/glia.24290) (PMID:36354016)

Sunzini, F., Schrepf, A., Clauw, D. J. and Basu, N. (2023) The biology of pain: through the rheumatology lens. Arthritis and Rheumatology, (doi: 10.1002/art.42429) (PMID:36599071) (Early Online Publication)

V

Van Kuijk, A. W.R. et al. (2023) Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data. Rheumatology, (doi: 10.1093/rheumatology/kead089) (PMID:36810788) (Early Online Publication)

W

Ward, E. J. et al. (2023) Placental inflammation leads to abnormal embryonic heart development. Circulation, 147(12), pp. 956-972. (doi: 10.1161/CIRCULATIONAHA.122.061934) (PMID:36484244) (PMCID:PMC10022676)

Wasker, S. V. Z., Challoumas, D., Weng, W., Murrell, G. A.C. and Millar, N. L. (2023) Is neurogenic inflammation involved in tendinopathy? A systematic review. BMJ Open Sport and Exercise Medicine, 9(1), e001494. (doi: 10.1136/bmjsem-2022-001494) (PMID:36793930) (PMCID:PMC9923261)

Winthrop, K. L. et al. (2023) Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022. Annals of the Rheumatic Diseases, (doi: 10.1136/ard-2022-223528) (PMID:36702529) (Early Online Publication)